Efficacy and safety of diacerein in osteoarthritis of the knee: A double-blind, placebo-controlled trial

Pelletier, Jean‐Pierre; Yaron, Michael; Haraoui, Boulos; Cohen, Patrick; Nahir, M.; Choquette, D.; Wigler, Irena; Rosner, Itzhak; Beaulieu, André

doi:10.1002/1529-0131(200010)43:10<2339::aid-anr23>3.0.co;2-p

Cited by 157 publications

(124 citation statements)

References 18 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…Randomized controlled trial studies by Shafshak et al (2012) showed administration diacerein (100 mg/d) and diclofenac giving the difference of pain intensity in the pre and post treatment, both at 1 mo (p = 0.033) and 2 mo (p = 0.001) therapy [30]. A significant reduction effect in pain intensity after 4 w follow-up in this study was supported by the results of the other literature, which said that effects of diacerein appear 2-4 w after therapy, and were significant after 4-8 w [20]. Meloxicam reaches significant effects as an analgesic in 2 nd -4 th w [27].…”

Section: Discussionsupporting

confidence: 81%

See 1 more Smart Citation

Comparison of Pain Score in Osteoarthritis Patients Treated With a Combination of Diacerein and Meloxicam and Meloxicam Alone

Dwicandra¹,

Setiadi

2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: Osteoarthritis (OA) is a progressive chronic disease with the loss of articular cartilage. In managing OA, inadequate pain relief (IPR) often occurs, particularly with a single non steroidal anti-inflammatory drugs (NSAIDs) therapy. In this research, pain outcome of OA patients treated with a combination of diacerein and meloxicam vs meloxicam alone was evaluated.Methods: This research was conducted at rumah sakit umum daerah (RSUD) Dr. Mohammad Soewandhie Surabaya by using randomized controlled trial (RCT) design. Pain outcome was evaluated by pain intensity and area under the curve (AUC) of pain score in week 0-4 th .Results: There were a significantly different (p<0.05) in pain intensity seen in 3 rd and 4 th weeks after treated with a combination of diacerein and meloxicam, and with meloxicam only. However, there were no different in AUC pain score between combination and single therapy. Conclusion:Combination therapy of diacerein and meloxicam was more effective than meloxicam alone. A significant effect of a combination therapy of diacerein and meloxicam occurred at 3 rd weeks. The prolong study in order to get the differences in AUC pain score are needed.

show abstract

Section: Discussionsupporting

confidence: 81%

“…Several randomized controlled trials (RCTs) and meta-analysis studies showed the benefits of diacerein in the treatment of OA and others studies in the Cochrane library declared the absence of significant benefit of diacerein [13,[17][18][19][20][21][22]. Diacerein was reported having slow-acting properties.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Pain Score in Osteoarthritis Patients Treated With a Combination of Diacerein and Meloxicam and Meloxicam Alone

Dwicandra¹,

Setiadi

2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

show abstract

“…For a moderate difference between the groups, i.e., a Mann-Whitney coefficient of 0.64 or a Cohen effect size of 0.5, with a level of significance (␣) of 0.05 (2-sided) and 80% power, it was determined that a sample size of 69 patients per group was needed. Assuming a 20% dropout rate (22), the exact sample size to be included was 168. Double-data entry was performed in a blinded manner by an independent statistician (MD Research, Munich, Germany), using the program Report, version 6.4.12 (IDV).…”

Section: Methodsmentioning

confidence: 99%

Retracted: The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: A randomized, multicenter, double‐blind, placebo‐controlled study with primary end points at two months after the end of a three‐month treatment period

Pavelka

Trč

Karpas

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To determine whether the efficacy of diacerein persists at 2 months after the end of a 3-month treatment period, compared with placebo, in patients with painful knee osteoarthritis (OA).Methods. After a 1-week nonsteroidal antiinflammatory drug washout period, patients received either diacerein or placebo for 3 months, followed by an off-treatment period of 3 months to determine the carryover effects of the drug. Although patients were followed up through month 6, the primary efficacy end point was the percent change from baseline in pain (Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC] A) at month 5 (i.e., 2 months after the end of treatment) compared with placebo. The co-primary efficacy end point was the percent change from baseline in the total WOMAC score, also at month 5 versus placebo.Results. Two hundred three patients were screened, and 168 patients with painful knee OA were randomized. One hundred sixty-five patients were analyzed in an intent-to-treat analysis. At month 5, diacerein showed statistically significant superiority versus placebo as assessed with both the WOMAC A (P < 0.0001) and the total WOMAC (P < 0.0001), demonstrating the carryover effect of the drug. This superiority was already evident from month 2 for pain (P ‫؍‬ 0.001) and month 1 for total WOMAC (P ‫؍‬ 0.0021). Diacerein was safe and well tolerated. No serious or previously undocumented adverse events were observed during the study.Conclusion. This is the first published study of a symptomatic slow-acting OA drug in which the time of assessment of the primary outcome end points was 2 months after the end of a 3-month treatment period. The results show that diacerein is safe and effective for the treatment of knee OA and has a long carryover effect.Osteoarthritis (OA) is a disease affecting synovial joints and is characterized by degradation and loss of articular cartilage with subchondral bone remodeling, osteophyte formation, and synovial membrane inflammation (1,2). Clinical signs include fluctuating joint pain, swelling, stiffness, and loss of mobility, which increase in severity as the disease progresses. In the absence of a curative agent, the main objectives of OA management are to reduce symptoms, minimize functional disability, and limit the progression of structural changes, with the ultimate goal of delaying or avoiding arthroplasty.

show abstract

“…Because of the well-known toxicity profiles of NSAID and analgesics, supplementary drugs or health food supplements, such as avocado/soybean, diacerein, glucosamine and chondroitin, have widely been used (McAlindon et al, 2000;Pelletier et al, 2000;Christensen et al, 2008).…”

Section: Discussionmentioning

confidence: 99%

Effects of AIF on Knee Osteoarthritis Patients: Double-blind, Randomized Placebo-controlled Study

Park

Kim

Shin

et al. 2009

Korean J Physiol Pharmacol

View full text Add to dashboard Cite

Efficacy and safety of diacerein in osteoarthritis of the knee: A double-blind, placebo-controlled trial

Abstract: Diacerein, a drug for the treatment of OA, was shown to be an effective treatment for symptoms in patients with knee OA. Taking into account both efficacy and safety, the optimal daily dosage of diacerein for patients with knee OA is 100 mg/day (50 mg twice daily).

Cited by 157 publications

References 18 publications

Comparison of Pain Score in Osteoarthritis Patients Treated With a Combination of Diacerein and Meloxicam and Meloxicam Alone

Comparison of Pain Score in Osteoarthritis Patients Treated With a Combination of Diacerein and Meloxicam and Meloxicam Alone

Retracted: The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: A randomized, multicenter, double‐blind, placebo‐controlled study with primary end points at two months after the end of a three‐month treatment period

Effects of AIF on Knee Osteoarthritis Patients: Double-blind, Randomized Placebo-controlled Study

Contact Info

Product

Resources

About